SCHEMBL30060152

SCHEMBL30060152

Oc1cccc(Nc2nc(-c3ccccn3)cs2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MBD2 Q9UBB5 2/20 1.00
NR4A1 P22736 1/20 0.74
VCP P55072 1/20 0.74
MAPT P10636 3/20 0.72
MEN1 O00255 3/20 0.72
KMT2A Q03164 3/20 0.72
SMN1; SMN2 Q16637 2/20 0.72
NR1I2 O75469 1/20 0.72
NFKB1 P19838 1/20 0.72
PPP1CA P62136 1/20 0.72
NFKB2 Q00653 1/20 0.72
RELA Q04206 1/20 0.72
NPSR1 Q6W5P4 1/20 0.72
CSNK2A2 P19784 1/20 0.72
CSNK2B P67870 1/20 0.72
ALOX5 P09917 2/20 0.70
CYP1A1 P04798 2/20 0.65
CYP1A2 P05177 2/20 0.65
CYP1B1 Q16678 2/20 0.65
NPC1 O15118 3/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13390238 1.00 MBD2 (1.00) MBD2NR4A1VCPMAPTMEN1
SCHEMBL1890717 0.85 MAPT (0.74) MBD2NR4A1VCPMAPTMEN1
SCHEMBL1887374 0.85 VCP (1.00) MBD2NR4A1VCPMAPTMEN1
SCHEMBL12639826 0.84 SMN1; SMN2 (1.00) MBD2NR4A1VCPMAPTMEN1
SCHEMBL4742547 0.82 ALOX5 (1.00) MBD2VCPMAPTMEN1KMT2A
SCHEMBL17071970 0.82 KCNN1 (0.73) MBD2NR4A1VCPMAPTMEN1
SCHEMBL7678939 0.81 MAPT (0.81) MBD2NR4A1VCPMAPTMEN1
SCHEMBL486534 0.81 ALOX5 (0.82) MBD2VCPMAPTMEN1KMT2A
SCHEMBL23553573 0.81 NPY5R (0.76) MBD2NR4A1VCPMAPTMEN1
Bromide SCHEMBL7673197 0.80 MAPT (0.79) MBD2NR4A1VCPMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12419900-B2 Induction of synthetic lethality with epigenetic therapy THE JOHNS HOPKINS UNIVERSITY (US) 2025-09-23 US disclosed
US-20230100402-A1 INDUCTION OF SYNTHETIC LETHALITY WITH EPIGENETIC THERAPY THE JOHNS HOPKINS UNIVERSITY 2023-03-30 US disclosed
US-11491174-B2 Induction of synthetic lethality with epigenetic therapy THE JOHNS HOPKINS UNIVERSITY (US) 2022-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11491174-B2 Induction of synthetic lethality with epigenetic therapy MCL1, BAD, ACIN1 MBD2 219/4885NR4A1 3817/4885VCP 3269/4885
US-20230100402-A1 INDUCTION OF SYNTHETIC LETHALITY WITH EPIGENETIC THERAPY MCL1, BAD, ACIN1 MBD2 219/4885NR4A1 3817/4885VCP 3269/4885
US-12419900-B2 Induction of synthetic lethality with epigenetic therapy MCL1, BAD, ACIN1 MBD2 219/4885NR4A1 3817/4885VCP 3269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.